- Affirmative Recovery
- American Indian Law and Policy
- Antitrust and Trade Regulation
- Appellate Advocacy and Guidance
- Business Litigation
- Childhood Sexual Abuse Litigation
- Class Action Litigation
- Commercial/Project Finance and Real Estate
- Corporate Governance and Special Situations
- Domestic and International Arbitration
- Ediscovery
- Health Care Litigation
- Insurance and Catastrophic Loss
- Intellectual Property and Technology Litigation
- Mass Tort Attorneys
- Medical Malpractice Attorneys
- Personal Injury Attorneys
- Restructuring and Business Bankruptcy
- Wealth Planning, Administration, and Disputes
- Litigation Support Services
-
January 17, 2020Patrick Arenz Named to America's Top 100 List for High-Stakes Litigation
-
January 08, 2020Bremer Bank Employee-Shareholders File Class Action Lawsuit Against Three Trustees of Otto Bremer Trust
-
January 08, 2020Robins Kaplan Adds Leading Civil Rights, Personal Injury Attorneys to Minneapolis Office
-
January 24, 2020Elimination of Bias: Seeing Juveniles with Justice
-
January 28, 2020Boston 1L Diversity Summer Associate Program Reception
-
January 29-30, 2020American Bar Association Tort Trial & Insurance Practice Section Fidelity & Surety Law Midwinter Conference
-
January 10, 2020Top Tips for Trying Your First (or Next) Patent Jury Trial
-
January 2020A Victory for All Involved
-
January 2020Facing the Music: Protecting Photography in the Age of Instagram
Beyond Preemption of Generic Drug Claims
2015
Recent research indicates that the current cost of generic medications in the United States is the highest in history. Many patients are no longer able to afford life saving medications that were once affordable only five years ago. Concurrent to the rising prices of generic drugs, pharmaceutical companies have lauded preemption as a necessary and viable solution to combat the increasing prices. Two recent Supreme Court decisions, PLIVA, Inc. v. Mensing and Mutual Pharmaceutical Co. v. Bartlett, have agreed with this logic, and have attempted to pervert the Hatch-Waxman Act, and its corresponding ANDA approval process to shield generic drug manufacturers from liability.
Recent research indicates that the current cost of generic medications in the United States is the highest in history.
The articles on our Website include some of the publications and papers authored by our attorneys, both before and after they joined our firm. The content of these articles should not be taken as legal advice.
Related Professionals
Eric M. Lindenfeld
Associate
Related Publications
Related News
If you are interested in having us represent you, you should call us so we can determine whether the matter is one for which we are willing or able to accept professional responsibility. We will not make this determination by e-mail communication. The telephone numbers and addresses for our offices are listed on this page. We reserve the right to decline any representation. We may be required to decline representation if it would create a conflict of interest with our other clients.
By accepting these terms, you are confirming that you have read and understood this important notice.